ClinicalTrials.gg
Not yet recruitingNCT07751094Updated Aug 7, 2026

A Study to Evaluate the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection in Participants With Moderate-to-Severe Non-Cancer Chronic Pain

A Phase 1 interventional study of KL0011034 injection and Alfentanil Hydrochloride Injection in Chronic Pain, sponsored by The Third Xiangya Hospital of Central South University. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by The Third Xiangya Hospital of Central South University · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will evaluate the drug-drug interaction between KL0011034 Injection and Alfentanil Hydrochloride Injection in participants with moderate-to-severe non-cancer chronic pain. The study consists of two parts. Part 1 is a single-center, randomized, open-label, parallel-design study to evaluate the safety, tolerability, and pharmacodynamics of the combination. Approximately 9 participants will be enrolled and randomized to one of three dose groups (n=3 per group). Part 2 is a single-center, randomized, open-label, three-sequence, three-period crossover study to evaluate the pharmacokinetic interaction, safety, tolerability, and pharmacodynamic effects. Approximately 18 participants will be enrolled and randomized to one of three sequences (n=6 per sequence), with a 3-day washout period between each period.

Read the detailed description

Study Design and Population:

This is a two-part, single-center, randomized, open-label study in participants with moderate-to-severe non-cancer chronic pain. Part 1 uses a parallel-group design, and Part 2 uses a three-sequence, three-period crossover design.

Part 1 (Safety, Tolerability, and Pharmacodynamics):

Approximately 9 participants will be randomized in a 1:1:1 ratio to one of three dose groups to receive a single combined dose of Alfentanil Hydrochloride Injection 5 μg/kg plus KL0011034 Injection at one of three dose levels (Group 1: 0.3 mg/kg; Group 2: 0.35 mg/kg; Group 3: 0.4 mg/kg). Pharmacodynamic and safety evaluations will be conducted, and participants will be discharged after the end-of-study examinations on Day 2 (D2). Based on the results from Part 1, the maximum dose of KL0011034 Injection among the three dose levels that is deemed safe and tolerable will be selected for use in Part 2.

Part 2 (Pharmacokinetic Interaction, Safety, Tolerability, and Pharmacodynamics):

Approximately 18 participants will be randomized in a 1:1:1 ratio to one of three sequences (A, B, or C), with 6 participants per sequence. Each participant will complete three open-label treatment periods (Day 1, Day 4, and Day 7), with a 3-day washout period between periods. The selected KL0011034 dose from Part 1 will be used in Part 2. Pharmacokinetic sampling, pharmacodynamic evaluations, and safety assessments will be performed during each period. Participants will be discharged after the end-of-study examinations on Day 8 (D8).

Sequence A: Period 1: KL0011034 Injection (selected dose); Period 2: Alfentanil Hydrochloride Injection 5 μg/kg; Period 3: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose).

Sequence B: Period 1: Alfentanil Hydrochloride Injection 5 μg/kg; Period 2: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose); Period 3: KL0011034 Injection (selected dose).

Sequence C: Period 1: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose); Period 2: KL0011034 Injection (selected dose); Period 3: Alfentanil Hydrochloride Injection 5 μg/kg.

02

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • Drug-Drug Interaction
  • KL0011034
  • Alfentanil
  • Pharmacokinetics
  • Non-Cancer Chronic Pain
03

In context

Chronic Pain

3,227 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

This study's planned enrollment of 27 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

The Third Xiangya Hospital of Central South University is the lead sponsor of 99 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Those who fully understand the purpose, content, process and possible risks of the trial, and voluntarily participate and sign the form;
  2. Male and female patients with moderate to severe non-cancerous chronic pain (such as patients with shoulder inflammation, chronic back pain, myofascial pain syndrome) aged between 18 and 55 years (inclusive of the boundary values), with a NRS score of >= 4;
  3. Male weight not less than 50.0 kg, female weight not less than 45.0 kg; (BMI) within the range of 19.0 to 26.0 kg/m2 (including the critical value);
  4. From the date of signing the informed consent form to the last administration of the trial medication within 3 months, the trial participants (and their partners) have no plans for conception, and the trial participants have no plans for sperm donation/egg donation; From the date of signing the informed consent form to the completion of the exit examination, the participants voluntarily adopt non-pharmacological measures; After the exit examination to the last 3 months after the last administration of the trial medication, the participants voluntarily adopt effective contraceptive measures;
  5. Able to communicate well with the researchers, willing and able to comply with the lifestyle restrictions stipulated in the protocol, and cooperate to complete the trial process.

Exclusion criteria

Exclusion Criteria:

  1. Known to be allergic to alfentanil or other opioid analgesics, etomidate or other anesthetic drugs, or to be of allergic constitution (such as allergy to two or more drugs, food or pollen), or prone to develop rashes, urticaria, etc., or having a history of allergic diseases, or known to be allergic to the or raw materials of this product;
  2. Having a history of head trauma, possible intracranial hypertension, cerebral aneurysm, cerebrovascular accident, or mental illness such as schizophrenia, mania, bipolar disorder, mental confusion, long-term use of psychotropic drugs or cognitive dysfunction;
  3. Having a history of serious cardiovascular diseases (such as hypertension, heart failure, severe arrhythmia, etc.) and/or heart diseases, family history of heart disease and/or unstable angina pectoris, or having had a myocardial infarction in the past 6 months;
  4. Having a history of other cardiovascular, endocrine, respiratory, digestive, urinary, nervous, hematological and/or lymphatic system diseases, and the investigator considers that it still has clinical significance during the screening;
  5. Having a history of anesthesia accidents, severe adverse reactions during anesthesia or family history of anesthesia accidents, or having for general anesthesia;
  6. Having difficulty breathing or suspected difficult airway or estimated difficulty in tracheal intubation (such as modified Mallampati score grade III-IV, congenital small tongue, maldevelopment of mandible, etc.);
  7. Having a history of airway diseases such as bronchial asthma, , sleep apnea syndrome, etc.;
  8. Having a history of adrenal insufficiency, adrenal tumor or hereditary biosynthesis disorder or hereditary acute porphyria;
  9. Having a surgical history within 3 months before screening, or not recovering from surgery, or having planned surgery during the trial;
  10. Having conditions, surgical history, diseases related to the use of the test drug, or any other special circumstances that may significantly affect drug absorption, distribution, metabolism and excretion;
  11. Abnormal results of physical examination, vital signs, full thoracic radiograph, abdominal B-ultrasound, laboratory tests (blood routine, urine routine, blood biochemistry, coagulation function) have clinical significance;
  12. Having abnormalities found during screening, such as >=450 ms (male) or >=460 ms (female), etc.;
  13. Positive for surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab), and syphilis spirochete antibody (TP-Ab);
  14. Having unprotected sexual behavior within 2 weeks before the first administration of the test drug;
  15. Female subjects during the screening period are in pregnancy or lactation, or have a positive pregnancy result;
  16. Having a history of drug abuse or drug dependence within the past 1 year, or having a positive urine drug screening at the time of screening;
  17. Having a history of alcohol abuse within 6 months before screening [that is, consuming more than 14 standard units of alcohol per week (1 unit = 360 ml of beer or 45 ml of 40% alcohol liquor or 150 ml of wine)], or being unwilling to stop drinking alcohol or any alcoholic products during the trial, or having a positive alcohol breath test at the time of screening;
  18. Having a history of smoking within 3 months before screening (daily smoking quantity >= 5 cigarettes), or being unwilling to stop using any tobacco products during the trial, or having a positive smoke test result at the time of screening;
  19. Having consumed excessive (8 cups or more, 1 cup = 250 ml) tea, coffee or caffeine-containing beverages (such as milk tea, cola, etc.) every day within 14 days before screening, or being unwilling to stop drinking these beverages during the trial;
  20. Individuals who consumed grapefruit/grapefruit juice, foods or beverages rich in xanthine components (such as shiitake mushrooms, white carp, black carp, whelk, white bream, oysters, white snapper, sea eel, duck liver, chicken liver, pork intestines, pork liver, beef liver, etc.) within 48 hours before the first administration of the test drug, or those who had any special diet that could affect the absorption, distribution, metabolism, or excretion of the drug;
  21. Individuals who had used any medication within 14 days before the first administration of the test drug, including prescription drugs, over-the-counter drugs, traditional Chinese medicines, health supplements, and vitamins;
  22. Individuals who had used inhibitors or inducers of or CYP2C19 (such as CYP3A4 inhibitors: sirivatinib, atalenti, edalizumab, telifast, clarithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, indinavir, nelfinavir, ritonavir, sapparin, tipranavir, lopinavir, nafamoxin, cobizumet; CYP3A4 inducers: apalutamide, enzalutamide, rumactat, mitotane, evolizumab, phenytoin, carbamazepine, rifampicin, St. John's wort; CYP2C19 inhibitors: fluvoxamine, fluconazole, fluoxetine, ticlopidine, phenabarbital, nalfurafine, voriconazole; CYP2C19 inducers: rifampicin, apalutamide, efavirenz, enzalutamide, phenytoin) within 1 month before the first administration of the test drug;
  23. Individuals who had been using sedative drugs and/or opioid analgesics for more than 3 months before screening;
  24. Individuals who had participated in any clinical trials and used the test drug/medical device within 3 months before the first administration of the test drug, or were still in the follow-up period of other trials;
  25. Individuals who had received inactivated vaccines within 1 month before screening, or received live/deleted vaccines within 3 months before screening, or planned to receive inactivated/live/deleted vaccines during the trial;
  26. Individuals who had undergone blood loss or blood donation or transfusion or received a total amount of blood products exceeding 400 ml within 3 months before screening, or planned to donate blood or undergo surgery within 1 month after the trial or after the trial ends;
  27. Individuals with difficulty in blood collection, or those who cannot tolerate venipuncture, or those with a history of fainting or needle shock;
  28. Individuals with poor compliance, or other situations that the researcher deems unsuitable for participation in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    1.Alfentanil 5 µg/kg + KL0011034 0.3 mg/kg

    Part 1: Participants receive a single dose of Alfentanil Hydrochloride Injection 5 μg/kg combined with KL0011034 Injection 0.3 mg/kg on Day 1. Safety, tolerability, and pharmacodynamic evaluations are conducted.

    Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection

  • Experimental
    2.Alfentanil 5 µg/kg + KL0011034 0.35 mg/kg

    Part 1: Participants receive a single dose of Alfentanil Hydrochloride Injection 5 μg/kg combined with KL0011034 Injection 0.35 mg/kg on Day 1. Safety, tolerability, and pharmacodynamic evaluations are conducted.

    Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection

  • Experimental
    3.Alfentanil 5 µg/kg + KL0011034 0.4 mg/kg

    Part 1: Participants receive a single dose of Alfentanil Hydrochloride Injection 5 μg/kg combined with KL0011034 Injection 0.4 mg/kg on Day 1. Safety, tolerability, and pharmacodynamic evaluations are conducted.

    Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection

  • Experimental
    4.Sequence A: KL0011034 → Alfentanil → Alfentanil + KL0011034

    Part 2, Sequence A: Participants receive three interventions across three periods (Day 1, Day 4, Day 7) with a 3-day washout between periods: Period 1: KL0011034 Injection (selected dose from Part 1); Period 2: Alfentanil Hydrochloride Injection 5 μg/kg; Period 3: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose from Part 1). Pharmacokinetic, pharmacodynamic, and safety evaluations are conducted.

    Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection

  • Experimental
    5. Sequence B: Alfentanil → Alfentanil + KL0011034 → KL0011034

    Part 2, Sequence B: Participants receive three interventions across three periods (Day 1, Day 4, Day 7) with a 3-day washout between periods: Period 1: Alfentanil Hydrochloride Injection 5 μg/kg; Period 2: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose from Part 1); Period 3: KL0011034 Injection (selected dose from Part 1). Pharmacokinetic, pharmacodynamic, and safety evaluations are conducted.

    Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection

  • Experimental
    6. Sequence C: Alfentanil + KL0011034 → KL0011034 → Alfentanil

    Part 2, Sequence C: Participants receive three interventions across three periods (Day 1, Day 4, Day 7) with a 3-day washout between periods: Period 1: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose from Part 1); Period 2: KL0011034 Injection (selected dose from Part 1); Period 3: Alfentanil Hydrochloride Injection 5 μg/kg. Pharmacokinetic, pharmacodynamic, and safety evaluations are conducted.

    Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection

Interventions

  • KL0011034 Injection is an investigational drug being studied for its analgesic properties in combination with alfentanil. It is administered via intravenous infusion. The dose levels evaluated are 0.3 mg/kg, 0.35 mg/kg, and 0.4 mg/kg in Part 1; the selected dose from Part 1 is used in Part 2.

  • Alfentanil Hydrochloride Injection is an opioid analgesic administered via intravenous bolus at a fixed dose of 5 μg/kg. It is used alone and in combination with KL0011034 Injection to evaluate drug-drug interaction.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of KL0011034

    Cmax of KL0011034 in plasma, determined by non-compartmental analysis of concentration-time data.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours

  2. Maximum Plasma Concentration (Cmax) of KL0011034 Metabolite A644S(A)-Z7

    Cmax of KL0011034 major metabolite A644S(A)-Z7 in plasma, determined by non-compartmental analysis of concentration-time data.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  3. Maximum Plasma Concentration (Cmax) of Alfentanil

    Cmax of Alfentanil in plasma, determined by non-compartmental analysis of concentration-time data.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.

  4. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of KL0011034

    AUC0-t of KL0011034 in plasma, determined by non-compartmental analysis using linear-log trapezoidal method.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours

  5. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of KL0011034 Metabolite A644S(A)-Z7

    AUC0-t of KL0011034 major metabolite A644S(A)-Z7 in plasma, determined by non-compartmental analysis using linear-log trapezoidal method.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours

  6. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Alfentanil

    AUC0-t of Alfentanil in plasma, determined by non-compartmental analysis using linear-log trapezoidal method.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours

  7. Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of KL0011034

    AUC0-∞ of KL0011034 in plasma, calculated as AUC0-t + Clast/λz.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours

  8. Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of KL0011034 Metabolite A644S(A)-Z7

    AUC0-∞ of KL0011034 major metabolite A644S(A)-Z7 in plasma, calculated as AUC0-t + Clast/λz.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours

  9. Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Alfentanil

    AUC0-∞ of Alfentanil in plasma, calculated as AUC0-t + Clast/λz.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing);immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours

Secondary outcomes

  1. Time to Maximum Plasma Concentration (Tmax) of KL0011034

    Tmax of KL0011034 in plasma, determined directly from concentration-time data.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  2. Time to Maximum Plasma Concentration (Tmax) of KL0011034 Metabolite A644S(A)-Z7

    Tmax of KL0011034 major metabolite A644S(A)-Z7 in plasma, determined directly from concentration-time data.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  3. Time to Maximum Plasma Concentration (Tmax) of Alfentanil

    Tmax of Alfentanil in plasma, determined directly from concentration-time data.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.

  4. Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of KL0011034

    AUC0-24h of KL0011034 in plasma, determined by non-compartmental analysis.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  5. Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of KL0011034 Metabolite A644S(A)-Z7

    AUC0-24h of KL0011034 major metabolite A644S(A)-Z7 in plasma, determined by non-compartmental analysis.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  6. Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of Alfentanil

    AUC0-24h of Alfentanil in plasma, determined by non-compartmental analysis.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.

  7. Elimination Half-Life (t1/2) of KL0011034

    Elimination half-life (t1/2) of KL0011034 in plasma, calculated as ln(2)/λz, where λz is the terminal elimination rate constant determined by log-linear regression of the terminal phase of the concentration-time curve. Unit: hours.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  8. Elimination Half-Life (t1/2) of KL0011034 Metabolite A644S(A)-Z7

    Elimination half-life (t1/2) of KL0011034 major metabolite A644S(A)-Z7 calculated as ln(2)/λz, where λz is the terminal elimination rate constant determined by log-linear regression of the terminal phase.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  9. Elimination Half-Life (t1/2) of Alfentanil

    Elimination half-life (t1/2) of Alfentanil calculated as ln(2)/λz, where λz is the terminal elimination rate constant determined by log-linear regression of the terminal phase.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.

  10. Apparent Volume of Distribution (Vd) of KL0011034

    Apparent volume of distribution (Vd) of KL0011034 calculated as Dose/(AUC0-∞ × λz).

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  11. Apparent Volume of Distribution (Vd) of KL0011034 Metabolite A644S(A)-Z7

    Apparent volume of distribution (Vd) of KL0011034 major metabolite A644S(A)-Z7 calculated as Dose/(AUC0-∞ × λz).

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  12. Apparent Volume of Distribution (Vd) of Alfentanil

    Apparent volume of distribution (Vd) of Alfentanil calculated as Dose/(AUC0-∞ × λz).

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.

  13. Clearance (CL) of KL0011034

    Total body clearance (CL) of KL0011034 calculated as Dose/AUC0-∞.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  14. Clearance (CL) of KL0011034 Metabolite A644S(A)-Z7

    Total body clearance (CL) of KL0011034 major metabolite A644S(A)-Z7 calculated as Dose/AUC0-∞.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  15. Clearance (CL) of Alfentanil

    Total body clearance (CL) of Alfentanil calculated as Dose/AUC0-∞.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.

  16. Terminal Elimination Rate Constant (λz) of KL0011034

    Terminal elimination rate constant (λz) of KL0011034 determined by log-linear regression of the terminal phase of the concentration-time curve.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  17. Terminal Elimination Rate Constant (λz) of KL0011034 Metabolite A644S(A)-Z7

    Terminal elimination rate constant (λz) of KL0011034 major metabolite A644S(A)-Z7 determined by log-linear regression of the terminal phase of the concentration-time curve.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  18. Terminal Elimination Rate Constant (λz) of Alfentanil

    Terminal elimination rate constant (λz) of Alfentanil determined by log-linear regression of the terminal phase of the concentration-time curve.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.

  19. Mean Residence Time (MRT0-∞) of KL0011034

    Mean residence time (MRT0-∞) of KL0011034 calculated as AUMC/AUC0-∞.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  20. Mean Residence Time (MRT0-∞) of KL0011034 Metabolite A644S(A)-Z7

    Mean residence time (MRT0-∞) of KL0011034 major metabolite A644S(A)-Z7 calculated as AUMC/AUC0-∞.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.

  21. Mean Residence Time (MRT0-∞) of Alfentanil

    Mean residence time (MRT0-∞) of Alfentanil calculated as AUMC/AUC0-∞.

    Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.

  22. Adverse Events and Serious Adverse Events

    Incidence, severity, and causality of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) assessed by clinical observation and participant reporting.

    Time frame: From signing of informed consent through study completion (up to Day 8 in Part 2); unresolved AEs followed every 2 weeks until resolution or stabilization, up to 28 days after last dose.

  23. Vital Signs

    Change from baseline in vital signs including blood pressure, pulse rate, respiratory rate, tympanic temperature, and oxygen saturation (SpO2).

    Time frame: Part 2: Screening, Day -1, pre-dose on Day 3 and Day 6, pre-dose and at 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours post-dose in each treatment period (Day 1, Day 4, Day 7), and on Day 8 (end-of-study).

  24. 12-Lead Electrocardiogram Parameters

    Change from baseline in 12-lead ECG parameters including heart rate, PR interval, QRS interval, and QT interval corrected using Fridericia's formula (QTcF).

    Time frame: Part 2: Screening, Day -1, pre-dose on Day 3 and Day 6, pre-dose and at 30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours post-dose in each treatment period (Day 1, Day 4, Day 7), and on Day 8 (end-of-study).

  25. Physical Examination

    Number of participants with clinically significant abnormalities in physical examination findings (skin, mucous membranes, lymph nodes, head, neck, chest, abdomen, spine/extremities, and nervous system), assessed by standard physical examination.

    Time frame: Part 2: Screening, Day -1, and Day 8 (end-of-study).

  26. Injection Site Reactions

    Incidence and severity of injection site reactions (pain, tenderness, erythema, and induration/swelling), assessed by physical examination of the injection site using a standardized assessment scale. Severity graded as mild, moderate, or severe.

    Time frame: Part 2: Pre-dose, immediately post-dose plus 30 seconds, and at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 6 hours post-dose in each treatment period (Day 1, Day 4, and Day 7).

  27. MOAA/S Sedation Score

    Sedation level assessed using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale. Sedation onset defined as first MOAA/S score ≤4; recovery defined as MOAA/S score of 5 on 3 consecutive assessments.

    Time frame: Part 1 and Part 2: From pre-dose (-5 minutes) at 20 seconds, 40 seconds, 1 minute, 1 minute 20 seconds, 1 minute 40 seconds, 2 minutes, 2 minutes 20 seconds, 2 minutes 40 seconds, 3 minutes, and every minute thereafter until full recovery plus 10 minutes

  28. Bispectral Index (BIS) Monitoring

    Continuous BIS monitoring to assess depth of sedation/anesthesia. Anesthesia onset defined as first BIS value ≤60; duration of BIS between 40 and 60 is recorded.

    Time frame: Part 1 and Part 2: From pre-dose (-5 minutes) continuously until full recovery plus 10 minutes (recorded every 1 minute); up to 10 minutes post-dose for participants with no response.

  29. Eyelash Reflex

    Time to loss of eyelash reflex and time to recovery of eyelash reflex after study drug administration.

    Time frame: Part 1 and Part 2: From pre-dose (-5 minutes) every 15 seconds until eyelash reflex recovery, with minimum assessment up to 2 minutes post-dose; for participants with no loss of reflex within 5 minutes post-dose, evaluated every 15 seconds up to 5 minute

  30. Modified Aldrete Score for Discharge Readiness

    Recovery assessed using the Modified Aldrete Score (evaluating activity, respiration, blood pressure, consciousness, and SpO2). Discharge criteria met when score ≥9 on 3 consecutive assessments.

    Time frame: Part 1 and Part 2: From awakening, every 2 minutes until discharge criteria met (score ≥9 on 3 consecutive assessments); for participants with no response, starting at 10 minutes post-dose, every 2 minutes until discharge criteria met.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this is a first-in-human or early-stage clinical trial involving a novel investigational drug. The data contain proprietary and confidential information that could compromise ongoing patent applications and future commercial development. Public data sharing at this stage may also violate our confidentiality agreements with the contract research organization (CRO) and regulatory authorities. Therefore, IPD sharing is not feasible until the drug receives market approval or the primary study results are fully published.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.

Of 60 phase 1 interventional studies under Chronic Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 56. This study's planned 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Aug 7, 2026
StartEst.
Jul 30, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07751094
Lead sponsor
The Third Xiangya Hospital of Central South University
Responsible party
Guoping Yang (Professor of Clinical Pharmacology, The Third Xiangya Hospital of Central South University) — Principal investigator
First posted
Aug 7, 2026
Start date
Jul 30, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Huang Jie
Contact
cellahuang1988@163.com
+86 731 8991 8665

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: KL0011034 · Alfentanil

Start the discussion